114 related articles for article (PubMed ID: 24444531)
1. Treatment adherence in concurrent chemoradiation in patients with locally advanced non-small cell lung carcinoma: results of daily intravenous prehydration.
Uyterlinde W; Chen C; Nijkamp J; Obbink MG; Sonke JJ; Belderbos J; van den Heuvel M
Radiother Oncol; 2014 Mar; 110(3):488-92. PubMed ID: 24444531
[TBL] [Abstract][Full Text] [Related]
2. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
3. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy.
Chen C; Uyterlinde W; Sonke JJ; de Bois J; van den Heuvel M; Belderbos J
Radiother Oncol; 2013 Aug; 108(2):337-41. PubMed ID: 24074814
[TBL] [Abstract][Full Text] [Related]
4. Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer.
Uyterlinde W; Chen C; Kwint M; de Bois J; Vincent A; Sonke JJ; Belderbos J; van den Heuvel M
Radiother Oncol; 2013 Jun; 107(3):392-7. PubMed ID: 23647749
[TBL] [Abstract][Full Text] [Related]
5. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
6. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy.
Kwint M; Uyterlinde W; Nijkamp J; Chen C; de Bois J; Sonke JJ; van den Heuvel M; Knegjens J; van Herk M; Belderbos J
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e223-8. PubMed ID: 22560551
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
Niho S; Kubota K; Nihei K; Sekine I; Sumi M; Sekiguchi R; Funai J; Enatsu S; Ohe Y; Tamura T
Clin Lung Cancer; 2013 Jan; 14(1):62-9. PubMed ID: 22633219
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
[TBL] [Abstract][Full Text] [Related]
9. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Wang J; Pang QS; Wang P; Wang J; Wang W
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
[TBL] [Abstract][Full Text] [Related]
11. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
12. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Ichinose Y; Seto T; Sasaki T; Yamanaka T; Okamoto I; Takeda K; Tanaka M; Katakami N; Sawa T; Kudoh S; Saka H; Nishimura Y; Nakagawa K; Fukuoka M
J Thorac Oncol; 2011 Dec; 6(12):2069-75. PubMed ID: 22052226
[TBL] [Abstract][Full Text] [Related]
13. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating.
van den Heuvel MM; Uyterlinde W; Vincent AD; de Jong J; Aerts J; Koppe F; Knegjens J; Codrington H; Kunst PW; Dieleman E; Verheij M; Belderbos J
Radiother Oncol; 2014 Jan; 110(1):126-31. PubMed ID: 24225233
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
16. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
17. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: a systematic review of the literature.
Koning CC; Wouterse SJ; Daams JG; Uitterhoeve LL; van den Heuvel MM; Belderbos JS
Clin Lung Cancer; 2013 Sep; 14(5):481-7. PubMed ID: 23751283
[TBL] [Abstract][Full Text] [Related]
20. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]